Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LV-SHMT2shRNA
- Development stage
- Preclinical
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies
- Administration
- Intravenous, Parenteral
01
Overview
LV-SHMT2shRNA is a lentiviral vector-mediated short hairpin RNA (shRNA) designed to knock down the expression of serine hydroxymethyltransferase 2 (SHMT2). SHMT2 is a key mitochondrial enzyme in one-carbon metabolism that catalyzes the reversible conversion of serine and tetrahydrofolate to glycine and 5,10-methylenetetrahydrofolate. In preclinical models of idiopathic pulmonary fibrosis (IPF), LV-SHMT2shRNA has been used to investigate the role of SHMT2 in metabolic reprogramming, specifically the shift from fatty acid oxidation to glycine metabolism that promotes myofibroblast apoptosis resistance. Knockdown of SHMT2 using this lentiviral construct has been shown to reverse the accumulation of glycine metabolites, promote myofibroblast apoptosis, downregulate fibrotic markers (such as α-SMA and Collagen I), and attenuate lung fibrosis in vivo.
- Other names
- lentivirus-mediated SHMT2 shRNALV-sh-SHMT2LV-sh-SHMT-2LV-sh-SHMT 2LV-shSHMT2LV-shSHMT-2LV-shSHMT 2SHMT2 shRNA lentivirusSHMT-2 shRNA lentivirusSHMT 2 shRNA lentivirus
02
Targets
SHMT2 (Serine hydroxymethyltransferase 2)
Beyond the preview
Go deeper on LV-SHMT2shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LV-SHMT2shRNA.